Oncology Institute (TOI) director receives 17,185-share fully vested RSU grant

Rhea-AI Filing Summary

TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director Kimberly Jo Tzoumakas received a fully vested restricted stock unit (RSU) award of 17,185 shares of common stock on July 7, 2026. The grant is recorded at a price of $0.00 per share as equity compensation rather than an open-market purchase, and her directly held stake after this award is 17,185 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TZOUMAKAS KIMBERLY JO

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	17,185	$0.00	--

Holdings After Transaction: Common Stock — 17,185 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU shares granted: 17,185 shares Grant price: $0.00 per share Shares owned after grant: 17,185 shares

3 metrics

RSU shares granted 17,185 shares Common Stock grant on July 7, 2026

Grant price $0.00 per share Recorded transaction price for RSU award

Shares owned after grant 17,185 shares Total directly held after transaction

Key Terms

RSU, Grant, award, or other acquisition, Common Stock

3 terms

RSU financial

"Represents RSU award that was fully vested upon grant"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 04:30 PM Accepted by SEC EDGAR 07/09/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transaction did TOI director Kimberly Jo Tzoumakas report?

Director Kimberly Jo Tzoumakas reported receiving a grant of 17,185 shares of Oncology Institute common stock. The Form 4 classifies this as a grant, award, or other acquisition, not an open-market trade, and it is tied to a restricted stock unit award.

How many TOI shares were granted to Kimberly Jo Tzoumakas in this Form 4?

The filing shows a grant of 17,185 shares of Oncology Institute common stock. These shares come from a restricted stock unit award that was fully vested upon grant, increasing her directly held position to the same 17,185-share level.

Was the TOI insider transaction an open-market buy or a compensation grant?

The transaction is a compensation grant, not an open-market buy. The Form 4 uses transaction code A for a grant, award, or other acquisition, and the footnote states it represents an RSU award that was fully vested upon grant at a recorded price of $0.00 per share.

What is Kimberly Jo Tzoumakas’s TOI share ownership after this RSU grant?

After the transaction, she directly holds 17,185 shares of Oncology Institute common stock. The Form 4 lists this amount as the total shares following the transaction, reflecting the full impact of the vested restricted stock unit award on her direct ownership.

What does the RSU footnote in the TOI Form 4 explain?

The footnote explains that the reported shares represent a restricted stock unit award that was fully vested upon grant. This clarifies the transaction as immediate equity compensation, rather than a time-vested award or a purchase in the open market by the director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZOUMAKAS KIMBERLY JO

(Last) (First) (Middle)

18000 STUDEBAKER ROAD,

SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		A(1)		17,185	A	$0.00	17,185	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents RSU award that was fully vested upon grant

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Kimberly J. Tzoumakas	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)